Brokerages Set Q32 Bio Inc. (NASDAQ:QTTB) Target Price at $72.33

Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $72.33.

Several equities research analysts have weighed in on QTTB shares. Wells Fargo & Company started coverage on shares of Q32 Bio in a research report on Wednesday, September 11th. They issued an "overweight" rating and a $95.00 price objective for the company. Raymond James began coverage on shares of Q32 Bio in a research report on Thursday, October 24th. They issued a "strong-buy" rating and a $90.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Atlas Venture Life Science Advisors LLC bought a new position in Q32 Bio during the 1st quarter worth approximately $35,649,000. Carlyle Group Inc. bought a new position in Q32 Bio during the 1st quarter worth approximately $18,074,000. ARCH Venture Management LLC bought a new position in Q32 Bio during the 1st quarter worth approximately $5,461,000. Harvard Management Co. Inc. bought a new position in Q32 Bio during the 2nd quarter worth approximately $2,925,000. Finally, Platinum Investment Management Ltd. bought a new position in Q32 Bio during the 1st quarter worth approximately $1,874,000. Institutional investors own 31.32% of the company's stock.

Q32 Bio Price Performance

QTTB traded up $0.91 during midday trading on Thursday, hitting $47.23. The company had a trading volume of 80,541 shares, compared to its average volume of 67,118. The company has a debt-to-equity ratio of 0.37, a quick ratio of 6.49 and a current ratio of 6.49. The company has a market capitalization of $569.59 million, a PE ratio of -2.05 and a beta of -0.32. Q32 Bio has a twelve month low of $8.24 and a twelve month high of $53.79. The firm's 50-day simple moving average is $45.32 and its 200-day simple moving average is $33.46.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.42). Equities research analysts predict that Q32 Bio will post -11.76 EPS for the current fiscal year.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.